On the public citation graph
An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
0 signed · 86 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cncr.28130openalex-snapshot
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831
inferredcites →https://doi.org/10.1002/ijc.2910340210openalex-snapshot
Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumors
inferredcites →https://doi.org/10.1007/bf02968047openalex-snapshot
Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study
inferredcites →https://doi.org/10.1007/s10549-016-4000-zopenalex-snapshot
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
inferredcites →https://doi.org/10.1007/s13277-011-0180-7openalex-snapshot
Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)
inferredcites →https://doi.org/10.1016/b978-0-08-030764-0.50232-9openalex-snapshot
Monoclonal Antibodies against Human Milkfat Globule Membranes Useful in Carcinoma Research
inferredcites →https://doi.org/10.1016/j.bbcan.2012.03.012openalex-snapshot
Challenges in the clinical utility of the serum test for HER2 ECD
inferredcites →https://doi.org/10.1016/j.cca.2014.11.001openalex-snapshot
Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer
inferredcites →https://doi.org/10.1016/j.cca.2015.06.022openalex-snapshot
Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients
inferredcites →https://doi.org/10.1016/j.cca.2016.04.025openalex-snapshot
Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients
inferredcites →https://doi.org/10.1016/j.ctrv.2011.03.008openalex-snapshot
HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
inferredcites →https://doi.org/10.1016/j.ctrv.2013.06.003openalex-snapshot
Corrigendum to “HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer” [Cancer Treat Rev 2012; 38: 133–142]
inferredcites →https://doi.org/10.1016/s0959-8049(98)00297-4openalex-snapshot
The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers
inferredcites →https://doi.org/10.1016/s1470-2045(10)70297-7openalex-snapshot
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
inferredcites →https://doi.org/10.1038/bjc.1993.310openalex-snapshot
Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?
inferredcites →https://doi.org/10.1038/s41374-018-0033-8openalex-snapshot
The extracellular domain of Her2 in serum as a biomarker of breast cancer
inferredcites →https://doi.org/10.1056/nejmoa052122openalex-snapshot
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1413513openalex-snapshot
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1080/13547500902770090openalex-snapshot
Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences
inferredcites →https://doi.org/10.1089/hyb.1984.3.223openalex-snapshot
Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors
inferredcites →https://doi.org/10.1093/annonc/mdi059openalex-snapshot
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
inferredcites →https://doi.org/10.1093/annonc/mdm538openalex-snapshot
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes
inferredcites →https://doi.org/10.1093/annonc/mds604openalex-snapshot
Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer
inferredcites →https://doi.org/10.1093/clinchem/30.2.200openalex-snapshot
Roche RIA and Abbott EIA carcinoembryonic antigen assays compared.
inferredcites →https://doi.org/10.1093/clinchem/46.2.175openalex-snapshot
Automated Assay for HER-2/neu in Serum
inferredcites →https://doi.org/10.1126/science.3798106openalex-snapshot
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
inferredcites →https://doi.org/10.1159/000346844openalex-snapshot
Trastuzumab-Induced Hepatotoxicity: A Case Report
inferredcites →https://doi.org/10.1177/172460080401900301openalex-snapshot
ADVIA Centaur ® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer
inferredcites →https://doi.org/10.1186/bcr1020openalex-snapshot
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
inferredcites →https://doi.org/10.1186/s40064-015-1015-6openalex-snapshot
Monitoring serum HER2 levels in breast cancer patients
inferredcites →https://doi.org/10.1200/jco.1986.4.10.1542openalex-snapshot
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
inferredcites →https://doi.org/10.1200/jco.2008.16.8351openalex-snapshot
Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2008.17.3989openalex-snapshot
Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
inferredcites →https://doi.org/10.1200/jco.2009.23.4674openalex-snapshot
Value of Serum Human Epidermal Growth Factor Receptor 2 (HER2)/neu Testing for Early Prediction of Response to HER2/neu-Directed Therapies Is Still an Open One and Deserves Further Study in Large Prospective Trials
inferredcites →https://doi.org/10.1200/jco.2015.61.1459openalex-snapshot
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
inferredcites →https://doi.org/10.1200/jco.2015.61.8983openalex-snapshot
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines
inferredcites →https://doi.org/10.1200/jco.2015.62.4767openalex-snapshot
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer
inferredcites →https://doi.org/10.1309/ajcpirl4guvgk3yxopenalex-snapshot
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1373/clinchem.2005.059832openalex-snapshot
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
inferredcites →https://doi.org/10.1373/clinchem.2009.135566openalex-snapshot
Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer
inferredcites →https://doi.org/10.1515/cclm-2012-0488openalex-snapshot
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer
inferredcites →https://doi.org/10.3892/ol.2017.7164openalex-snapshot
Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients
inferredcites →https://doi.org/10.4137/bic.s12389openalex-snapshot
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?
inferredcites →https://doi.org/10.5301/jbm.2008.808openalex-snapshot
ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer
inferredcites →https://doi.org/10.7150/jca.13090openalex-snapshot
Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4087372openalex-extracted
Soluble Periostin is a Potential Biomarker for Chemotherapy Efficacy Monitoring in Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1002/ctm2.1687openalex-snapshot
Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial
inferred← citeshttps://doi.org/10.1007/978-981-99-2193-5_8openalex-snapshot
Role of Biomarkers in Cancer Prevention and Therapy
inferred← citeshttps://doi.org/10.1007/s00210-025-04687-7openalex-snapshot
Evaluation of serum tumor markers in assessing the efficacy of TP (Paclitaxel plus Carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual target therapy in HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1016/j.bulcan.2021.11.010openalex-snapshot
Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques
inferred← citeshttps://doi.org/10.1016/j.cca.2024.117792openalex-snapshot
Biomarker-specific biosensors revolutionise breast cancer diagnosis
inferred← citeshttps://doi.org/10.1016/j.cca.2026.121019openalex-snapshot
ISG15 as a novel serum biomarker for breast Cancer: Diagnostic and prognostic significance, clinical laboratory applications, and multi-biomarker integration strategies
inferred← citeshttps://doi.org/10.1038/s41598-026-37937-6openalex-snapshot
Clinical impact of the methylation status of SMAD4 and AKR1B1 genes in a liquid biopsy sample as a prognostic marker for breast cancer
inferred← citeshttps://doi.org/10.1063/5.0329694openalex-snapshot
Detection the SNPs of MUC1 gene cancer antigen 15-3 in blood patients with breast tumors
inferred← citeshttps://doi.org/10.1080/15321819.2026.2673316openalex-snapshot
Elevated parathyroid hormone-related peptide serum levels were associated with breast cancer tumor progression
inferred← citeshttps://doi.org/10.1093/jncics/pkab066openalex-snapshot
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
inferred← citeshttps://doi.org/10.1097/md.0000000000035361openalex-snapshot
FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer
inferred← citeshttps://doi.org/10.1109/spices52834.2022.9774245openalex-snapshot
A Survey on Various Combination of Breast Cancer Biomarkers
inferred← citeshttps://doi.org/10.1155/2022/7984591openalex-snapshot
Diagnostic Value of Dynamic Enhanced Magnetic Resonance Imaging Combined with Serum CA15-3, CYFRA21-1, and TFF1 for Breast Cancer
inferred← citeshttps://doi.org/10.1186/s12885-022-09864-yopenalex-snapshot
Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction
inferred← citeshttps://doi.org/10.1186/s12935-022-02523-zopenalex-snapshot
MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
inferred← citeshttps://doi.org/10.1186/s12935-024-03298-1openalex-snapshot
Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
inferred← citeshttps://doi.org/10.1186/s13046-024-03105-9openalex-snapshot
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
inferred← citeshttps://doi.org/10.1186/s13058-020-01290-xopenalex-snapshot
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
inferred← citeshttps://doi.org/10.1186/s13256-023-04088-5openalex-snapshot
Elevation of cancer antigen 15-3 owing to oncocytic renal neoplasm in a patient without evidence of breast cancer recurrence on follow-up: a case report
inferred← citeshttps://doi.org/10.2147/bctt.s331844openalex-snapshot
Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics
inferred← citeshttps://doi.org/10.2174/2211738508666200128120142openalex-snapshot
Cancer Fighting SiRNA-RRM2 Loaded Nanorobots
inferred← citeshttps://doi.org/10.22092/ari.2022.360239.2566openalex-snapshot
Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
inferred← citeshttps://doi.org/10.22159/ijap.2025.v17s1.12openalex-snapshot
IMPACT OF THE COMBINATION OF DOXORUBICIN, CYCLOPHOSPHAMIDE, AND DOCETAXEL ON CA 15-3 BIOMARKER LEVELS IN BREAST CANCER PATIENTS: A COMPARATIVE STUDY BETWEEN DELAYED AND NON-DELAYED CHEMOTHERAPY
inferred← citeshttps://doi.org/10.3233/cbm-230396openalex-snapshot
Involvement of FAM170B-AS1 , hsa-miR-1202 , and hsa-miR-146a-5p in breast cancer
inferred← citeshttps://doi.org/10.3389/fonc.2025.1602489openalex-snapshot
Approaches to modeling cancer metastasis: from bench to bedside
inferred← citeshttps://doi.org/10.3390/ani13193059openalex-snapshot
A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions
inferred← citeshttps://doi.org/10.3390/bios16050276openalex-snapshot
A Comparison of Cost-Effective Sensors for a Fluorescence-Based Detection System Used in Biodiagnostic Devices
inferred← citeshttps://doi.org/10.3390/cancers16203461openalex-snapshot
Salivary Transmembrane Mucins of the MUC1 Family (CA 15-3, CA 27.29, MCA) in Breast Cancer: The Effect of Human Epidermal Growth Factor Receptor 2 (HER2)
inferred← citeshttps://doi.org/10.6084/m9.figshare.12386327openalex-snapshot
Additional file 1 of Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.20306743openalex-snapshot
Additional file 1 of Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction
inferred← citeshttps://doi.org/10.6084/m9.figshare.20306746openalex-snapshot
Additional file 2 of Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction
inferred← citeshttps://doi.org/10.6084/m9.figshare.25440929openalex-snapshot
Additional file 1 of Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.25441047openalex-snapshot
Additional file 2 of Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26143637openalex-snapshot
Additional file 1 of Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
inferred← citeshttps://doi.org/10.6084/m9.figshare.26695491openalex-snapshot
Additional file 3 of Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26695494openalex-snapshot
Additional file 4 of Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26695497openalex-snapshot
Additional file 5 of Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26695500openalex-snapshot
Additional file 6 of Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26695503openalex-snapshot
Additional file 7 of Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.